Literature DB >> 16636569

Estimating the intelligibility of speakers with dysarthria.

Katherine C Hustad1.   

Abstract

Many speakers with dysarthria have reduced intelligibility, and improving intelligibility is often a primary intervention objective. Consequently, measurement of intelligibility provides important information that is useful for clinical decision-making. The present study compared two different measures of intelligibility obtained in audio-only and audio-visual modalities for 4 different speakers with dysarthria (2 with mild-moderate dysarthria; 2 with severe dysarthria) secondary to cerebral palsy. A total of 80 college-aged listeners provided word-by-word transcriptions and made percent estimates of intelligibility which served as dependent variables. Group results showed that transcription measures were higher than percent estimates of intelligibility overall. There was also an interaction between speakers and measures of intelligibility, indicating that the difference between transcription scores and percent estimates varied among individual speakers. Results revealed a significant main effect for presentation modality, with the audio-visual modality having slightly higher scores than the audio-only modality; however, presentation modality did not interact with speakers or with measures of intelligibility. Results suggest that standard clinical measurement of intelligibility using orthographic transcription may be more consistent than the use of more subjective percent estimates.

Entities:  

Mesh:

Year:  2006        PMID: 16636569     DOI: 10.1159/000091735

Source DB:  PubMed          Journal:  Folia Phoniatr Logop        ISSN: 1021-7762            Impact factor:   0.849


  9 in total

1.  Effects of speaking task on intelligibility in Parkinson's disease.

Authors:  Kris Tjaden; Greg Wilding
Journal:  Clin Linguist Phon       Date:  2010-10-01       Impact factor: 1.346

2.  Vowel contrast and speech intelligibility in dysarthria.

Authors:  Heejin Kim; Mark Hasegawa-Johnson; Adrienne Perlman
Journal:  Folia Phoniatr Logop       Date:  2010-10-12       Impact factor: 0.849

3.  Validation of an Acoustic-Based Framework of Speech Motor Control: Assessing Criterion and Construct Validity Using Kinematic and Perceptual Measures.

Authors:  Hannah P Rowe; Kaila L Stipancic; Adam C Lammert; Jordan R Green
Journal:  J Speech Lang Hear Res       Date:  2021-11-04       Impact factor: 2.674

4.  "You Say Severe, I Say Mild": Toward an Empirical Classification of Dysarthria Severity.

Authors:  Kaila L Stipancic; Kira M Palmer; Hannah P Rowe; Yana Yunusova; James D Berry; Jordan R Green
Journal:  J Speech Lang Hear Res       Date:  2021-11-11       Impact factor: 2.674

5.  Comparison of Intelligibility Measures for Adults With Parkinson's Disease, Adults With Multiple Sclerosis, and Healthy Controls.

Authors:  Kaila L Stipancic; Kris Tjaden; Gregory Wilding
Journal:  J Speech Lang Hear Res       Date:  2016-04-01       Impact factor: 2.297

6.  Assessment and management of the communication difficulties of children with cerebral palsy: a UK survey of SLT practice.

Authors:  Rose Mary Watson; Lindsay Pennington
Journal:  Int J Lang Commun Disord       Date:  2015-02-04       Impact factor: 3.020

7.  The effects of intensive speech treatment on intelligibility in Parkinson's disease: A randomised controlled trial.

Authors:  Erika S Levy; Gemma Moya-Galé; Young Hwa M Chang; Katherine Freeman; Karen Forrest; Mitchell F Brin; Lorraine A Ramig
Journal:  EClinicalMedicine       Date:  2020-06-28

8.  Feasibility of a Telerehabilitation Adaptation of the Be Clear Speech Treatment Program for Non-Progressive Dysarthria.

Authors:  Brooke-Mai Whelan; Deborah Theodoros; Louise Cahill; Atiyeh Vaezipour; Adam P Vogel; Emma Finch; Anna Farrell; Elizabeth Cardell
Journal:  Brain Sci       Date:  2022-01-31

9.  The Reliability and Validity of Speech-Language Pathologists' Estimations of Intelligibility in Dysarthria.

Authors:  Micah E Hirsch; Austin Thompson; Yunjung Kim; Kaitlin L Lansford
Journal:  Brain Sci       Date:  2022-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.